GS-EU-313-4172 (ZEUS) (R/R)
Safety Profile of Idelalisib in Patients With Refractory Follicular Lymphoma (ZEUS)
Study treatment
| Group/Cohort | Intervention/treatment |
|---|---|
| Idelalisib
Participants who have been or are currently being treated with 100 or 150 mg of idelalisib |
Tablets idelalisib administered according to the product information and treatment guidelines in routine clinical practice |
Inclusion criteria
Individuals who were or are being treated for refractory FL according to the product information for idelalisib and treatment guidelines in routine clinical practice
Exclusion criteria
Individuals included in clinical trials on idelalisib within the timeframe of this study.
Participating sites
ZNA